Delving into the Latest Updates on JK-0564 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Tianjin Jikun Pharmaceutical Technology Co., Ltd.

Active Organization

Tianjin Jikun Pharmaceutical Technology Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

剂量递增阶段为评价JK0564治疗标准治疗失败的晚期恶性实体瘤患者的安全性和耐受性，并探索JK0564的最大耐受剂量（MTD）。剂量扩展阶段为评价JK0564治疗标准治疗失败的晚期恶性实体瘤患者的安全性，确定Ⅱ期临床试验推荐剂量（RP2D）。

[Translation]

The dose escalation phase is to evaluate the safety and tolerability of JK0564 in patients with advanced malignant solid tumors who have failed standard treatment, and to explore the maximum tolerated dose (MTD) of JK0564. The dose expansion phase is to evaluate the safety of JK0564 in patients with advanced malignant solid tumors who have failed standard treatment, and to determine the recommended dose (RP2D) for Phase II clinical trials.

Start Date24 Oct 2023

Sponsor / Collaborator

Tianjin Jikun Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with JK-0564

Login to view more data

100 Translational Medicine associated with JK-0564

Login to view more data

100 Patents (Medical) associated with JK-0564

Login to view more data

100 Deals associated with JK-0564

Login to view more data